Whistleblower Speaks Out about Recent J&J Settlement, 250 Risperdal Lawsuit Claims Now Filed in PA

Published on December 11, 2013 by Laurie Villanueva

Text-Size:A A A+

 

In the latest Risperdal lawsuit news to follow last month’s $2.2 billion settlement from Johnson & Johnson, a former sales representative for the company is the latest to speak out about her experiences as a whistleblower for the U.S. federal government.

According to a Bloomberg.com report from December 9th, 2013, the woman says she went to a national company sales meeting in 2004 wearing a recording device planted by U.S. prosecutors who had begun to speculate about its off-label promotion of the anti-psychotic drug, Risperdal, and certain other medications. “I was concerned that I would be found out accidentally and someone would see me go into a room to meet the agent,” Doetterl said. “I had to change battery packs every four hours. I knew in the end I was doing the right thing. They needed to know what was going on.”

That was in 2004; nine years before Johnson & Johnson agreed to pay more than $2 billion worth of criminal and civil penalties brought by the U.S. Department of Justice. Among other things, the company and its subsidiary, Janssen Pharmaceuticals Inc., were accused of promoting Risperdal to elderly patients with dementia as well as children, even though Risperdal in children was not approved until 2006. Elderly patients with dementia were never approved to be treated with the medication.

Although Johnson & Johnson agreed to settle claims brought against them in a settlement reached on November 4th, the company “accepts accountability” for the actions described in the misdemeanor plea, the civil settlement “is not an admission of any liability or wrongdoing, and the company expressly denies the government’s civil allegations.”

250 Risperdal Lawsuits Now Pending in Philadelphia State Litigation

Meanwhile, growing number of product liability Risperdal gynecomastia claims from individuals who allegedly experienced male breast growth and other complications caused by the drug have been filed in the U.S. Court documents indicate that some 250 lawsuits are currently underway in the Philadelphia Court of Common Pleas.

A Bloomberg report from 2012 indicates that at least five Risperdal gynecomastia claims filed in the Pennsylvania state court litigation have already been settled by the manufacturer.

Filing a Claim Alleging Risperdal Gynecomastia

If you or a man you love experienced male breast growth, or Risperdal gynecomastia complications after taking the medication, you may be eligible to seek compensation for your injuries. Call the lawyers at Bernstein Liebhard LLP at .